34824-32-3

Upstream product

• 528-90-5 2,4,5-trimethylbenzoic acid 

Downstream Products

• 92492-87-0 2,4,5-trimethyl-benzoic acid-(2-dimethylamino-ethylamide) 
• 69186-97-6 2,4,5-Trimethyl-benzoic acid 2,2-dimethyl-1-(2,4,5-trimethyl-phenyl)-propyl ester 
• 114056-83-6 (3-Hydroxy-isoxazolidin-2-yl)-(2,4,5-trimethyl-phenyl)-methanone 
• 145192-96-7 N-<(1S)-4-oxocycloheptyl>-2,4,6-trimethylbenzamide 
• 937261-48-8 2,4,5,N-tetramethyl-benzamide 
• 123103-15-1 9-(2,4,5-Trimethyl-benzoyl)-1,2,3,4-tetrahydro-phenanthren 
• 114056-73-4 2,4,5-trimethylbenzohydroxamic acid 
• 145192-95-6 N-cycloheptyl-2,4,6-trimethylbenzamide 
• 34824-33-4 9-(2,4,5-Trimethyl-benzoyl)-phenanthren 
• 102948-88-9 pyren-1-yl-(2,4,5-trimethyl-phenyl)-ketone 

Relevant academic research and scientific papers

Novel potent and efficacious nonpeptidic urotensin II receptor agonists

Six different series of nonpeptidic urotensin II receptor agonists have been synthesized and evaluated for their agonistic activity in a cell-based assay (R-SAT). The compounds are ring-opened analogues of the isochromanone-based agonist AC-7954 with different functionalities constituting the linker between the two aromatic ring moieties. Several of the compounds are highly potent and efficacious, with N-[1-(4-chlorophenyl)-3-(dimethylamino)- propyl]-4-phenylbenzamide oxalate (5d) being the most potent. The pure enantiomers of 5d were obtained from the corresponding diastereomeric amides. It was shown by a combination of X-ray crystallography and chemical correlation that the activity resides in the S-enantiomer of 5d (pEC50 7.49).

Isochromanone-based urotensin-II receptor agonists

A series of analogues of the selective non-peptide urotensin II (UII) receptor agonist 3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)-isochroman-1-one (AC-7954, 1) was synthesized and evaluated for UII agonist activity using a functional cell-based assay. The introduction of a methyl group in the 4-position resulted in a complete loss of activity, whereas substituents in the aromatic rings were beneficial. Sterically demanding amino groups were also detrimental to the activity. Several potent agonists were identified, six compounds being equally or more potent than 1. The most potent compound in the series was the 6,7-dimethyl analogue of 1 (16, pEC50 6.87). The racemate of 16 was resolved into the pure enantiomers using preparative straight phase HPLC. It was shown that the potency resides in the (+)-enantiomer (pEC50 7.11). The synthesized compounds seem to be selective for the UII receptor as no activities were observed at the closely related SSTR3 and 5 receptors.